Evidence map›Paper›PMID 29331381›Full record

Trial reportClinical genitourinary cancer2018

Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.

Edoardo Francini, Steven Yip, Shubidito Ahmed, Haocheng Li, Luke Ardolino, Carolyn P Evan, Marina Kaymakcalan, Grace K Shaw, Philip W Kantoff, Mary-Ellen Taplin and 4 more

Open access · bronzeAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical genitourinary cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 4 countries.

Edoardo FranciniDana-Farber Cancer Institute, Harvard Medical School, Boston, MA; Sapienza Università di Roma, Rome, Italy.
Steven YipTom Baker Cancer Centre, Calgary, AB, Canada.
Shubidito AhmedTom Baker Cancer Centre, Calgary, AB, Canada.
Haocheng LiDepartments of Oncology and Community Health Sciences, University of Calgary, Calgary, AB, Canada.
Luke ArdolinoSt Vincent's Hospital, Sydney, Australia.
Carolyn P EvanDana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Marina KaymakcalanDana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Grace K ShawDana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Philip W KantoffMemorial Sloan Kettering Cancer Center, New York, NY.
Mary-Ellen TaplinDana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Nimira S AlimohamedTom Baker Cancer Centre, Calgary, AB, Canada.
Anthony M JoshuaSt Vincent's Hospital, Sydney, Australia.
Daniel Y C HengTom Baker Cancer Centre, Calgary, AB, Canada.
Christopher J SweeneyDana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Electronic address: christopher_sweeney@dfci.harvard.edu.
Harvard University · USSt Vincent's Hospital Sydney · AUMemorial Sloan Kettering Cancer Center · USUniversity of Calgary · CA

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundThe CHAARTED (ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer) and STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) trials showed that the addition of docetaxel (D) to androgen deprivation therapy (ADT) prolonged longevity of men with metastatic hormone-sensitive prostate cancer (mHSPC). However, the impact of upfront D on subsequent therapies is still unexplored. As abiraterone acetate (AA) and enzalutamide (E) are the most commonly used first-line treatment for metastatic castration-resistant prostate cancer (mCRPC), we aimed to assess whether they maintained their efficacy after ADT+D versus ADT alone. PATIENTS AND

methodsA cohort of patients with mCRPC treated between 2014 and 2017 with first-line AA or E for mCRPC was identified from 3 hospitals' institutional review board-approved databases. Patients were classified by use of D for mHSPC. This time frame was chosen as ADT+D became a valid therapeutic option for mHSPC in 2014, and it inherently entailed a short follow-up time on AA/E. The endpoints included overall survival from ADT start, overall survival from AA/E start, and time to AA/E start from ADT start. Differences between groups were assessed using the log-rank test.

resultsOf the 102 patients with mCRPC identified, 50 (49%) had previously received ADT alone, while 52 (51%) had ADT+D. No statistically significant difference in any of the evaluated outcomes was observed between the 2 cohorts. Yet, deaths in the ADT+D group were 12 versus 21 in the ADT alone, after a median follow-up of 24.4 and 29.8 months, respectively.

conclusionIn a cohort of ADT/ADT+D-treated patients with mCRPC with short times to first-line AA/E and follow-up, the efficacy of AA/E is similar regardless of previous use of D.

Indexed as

Abiraterone AcetateAntineoplastic Combined Chemotherapy ProtocolsBenzamidesDisease-Free SurvivalDocetaxelHumansMaleNitrilesPhenylthiohydantoinProstatic Neoplasms, Castration-ResistantRetrospective StudiesSurvival AnalysisTreatment OutcomeAbiraterone AcetateBenzamidesDocetaxelenzalutamideNitrilesPhenylthiohydantoinAR targeting agentsCHAARTEDmCRPCmCRPC sequencingmHSPC

Identifiers

PMID29331381
PMCPMC5986287
OpenAlexW2776594178

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.